Resources Repository
-
ArticlePublication 2021Global Costs, Health Benefits, & Economic Benefits of Scaling Up Treatment and Imaging Modalities for Survival of 11 Cancers
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging …
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival in 200 countries/territories for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). Using a microsimulation model of global cancer survival, the paper evaluated the costs and health and economic benefits of scaling up packages of treatment (chemotherapy, surgery, radiotherapy, and targeted…
Priority Setting/Ethics | Health Systems | Health Outcomes | Microsimulation | Benefit-Cost Analysis | Chronic Disease/Risk | Global -
ArticlePublication 2021Impact of Treatment and Imaging Modalities on Global Breast Cancer Survival
This analysis used a microsimulation model of global cancer survival to simulate 5-year net survival …
This analysis used a microsimulation model of global cancer survival to simulate 5-year net survival for women with newly diagnosed breast cancer in 200 countries/territories in 2018, accounting for the availability and stage-specific survival impact of specific treatment modalities (chemotherapy, radiotherapy, surgery, and targeted therapy), imaging modalities (ultrasound, x-ray, CT, MRI, PET, and single-photon emission computed tomography [SPECT]), and quality of cancer care. The model was calibrated to empirical data on 5-year net breast cancer…
Calibration/Validation | Health Systems | Health Outcomes | Microsimulation | Chronic Disease/Risk | Clinical Care | Global -
Tools/ModelsWeb Portal, Teaching Resource 2019Australia & New Zealand Health Intervention Interactive League Table
This interactive league table contains more than 800 Australian and New Zealand evaluations of public …
This interactive league table contains more than 800 Australian and New Zealand evaluations of public health intervention impacts on health gains (in quality/disability/health adjusted life years), health system costs and cost effectiveness. It allows users (policy-makers, researchers, health professionals, general public) to compare the health gains and costs associated with different interventions. The web portal provides access to a Users Guide and a Plain Language Summary of how to interpret table and graph outputs. Read the research…
Priority Setting/Ethics | Health Systems | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health/Medicine | Asia & Pacific | Oceania | College | Graduate | Doctoral | Professional | Graphics/Visualization -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Priority Setting/Ethics | Health Systems | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health/Medicine | Asia & Pacific | Oceania -
ArticlePublication 2020Infectious Disease Pandemic Planning and Response: Incorporating Decision Analysis
During a pandemic, decisions must be made under rapidly changing, uncertain conditions. Despite advances in …
During a pandemic, decisions must be made under rapidly changing, uncertain conditions. Despite advances in analytical methods for gaining early situational awareness (i.e., of a disease’s transmissibility and severity) and for predicting the likely effectiveness of interventions, a major gap exists globally in terms of integrating this information in policy documents. The authors argue that mathematical and statistical models are important tools for pandemic planning and response. Once an outbreak of pandemic potential has been…
Decision Analysis | Health Systems | Mathematical Models | Government/Law | Health/Medicine | Global -
ArticlePublication 2021Correct COVID-19 Vaccine Misinformation: Lancet Commission on COVID-19 Vaccines & Therapeutics Task Force Members
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 …
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 vaccines. In 2020, up to one-third or more of people surveyed both globally and in the U.S. indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted.…
Preferences/Values | Global Governance | Infectious Diseases | Social Determinants | Policy/Regulation | Culture/Society | Health/Medicine | Science/Technology | Global -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Priority Setting/Ethics | Health Systems | Health Outcomes | Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Ethiopian Health Decision Sciences
This resource pack provides a curated set of peer-reviewed articles that represent the growing evidence …
This resource pack provides a curated set of peer-reviewed articles that represent the growing evidence base for decision making and priority setting in Ethiopia - with an emphasis on improving health, reducing inequity, and preventing health-related impoverishment. Curated by Dr. Stéphane Verguet at the Center for Health Decision Science, most of the papers reflect work done as part of the Disease Control Priorities-Ethiopia (DCP-E) project. The pack provides scholarship that spans maternal-child health, vaccine-preventable disease, infectious…
Priority Setting/Ethics | Health Systems | Costing Methods | Health Outcomes | Mathematical Models | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | Health Systems | Test Performance | Technology Assessment | Infectious Diseases | Policy/Regulation | Government/Law | Health/Medicine | Global | North America